Tci GeneROCO:6879 65 FCF Margin % is 66.64% as of Dec. 2025, which is 201% above its 10-year median of 22.16. GuruFocus rates ROCO:6879 with a GF Score™ of 65/100 and a GF Value™ of NT$49.25 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 954 Biotechnology companies, Tci Gene ranks better than 97.38% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Tci Gene's Free Cash Flow for the
six
months ended in Dec. 2025 was NT$87.9 Mil. Tci Gene's Revenue for the
six
months ended in Dec. 2025 was NT$131.9 Mil. Therefore, Tci Gene's FCF Margin % for the quarter that ended in Dec. 2025 was 66.64%.
The historical rank and industry rank for Tci Gene's FCF Margin % or its related term are showing as below:
ROCO:6879'
s FCF Margin % Range Over the Past 10 Years
Min: 4.4 Med: 22.16 Max: 55.16
Current: 55.16
During the past 7 years, the highest FCF Margin % of Tci Gene was 55.16%. The lowest was 4.40%. And the median was 22.16%.
ROCO:6879's FCF Margin % is ranked better than 97.38% of 954
companies
in the Biotechnology industry
Industry Median: -84.535
vs ROCO:6879: 55.16
Tci Gene FCF Margin % Related Terms
Tci Gene FCF Margin % Historical Data
* Premium members only.
The historical data trend for Tci Gene's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6879 vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, Tci Gene's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tci Gene FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tci Gene's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Tci Gene's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tci Gene (ROCO:6879) has a FCF Margin % of 66.64% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Tci Gene and its competitors. This is 201% above median its historical median of 22.16. Over the past decade, Tci Gene's FCF Margin % has ranged from 4.40 to 55.16. According to the industry distribution chart, Tci Gene ranks #25 out of 954 companies in the Biotechnology industry, placing it in the top 2.6%.
Is Tci Gene's FCF Margin % too high?
Tci Gene's current FCF Margin % of 66.64% is 201% above median its 10-year median of 22.16. Over the past 10 years, this metric has ranged from a low of 4.40 to a high of 55.16. Based on the distribution chart, Tci Gene ranks #25 out of 954 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Tci Gene has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tci Gene's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Tci Gene ranks #25 out of 954 companies for FCF Margin %. This places Tci Gene in the top 3% of its industry — outperforming the majority of peers. Historically, Tci Gene's own FCF Margin % has ranged from 4.40 to 55.16 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Tci Gene and its competitors. Tci Gene's current FCF Margin % is 66.64%, which is 201% above median its own 10-year median of 22.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tci Gene stock overvalued right now?
Based on GuruFocus' analysis, Tci Gene (ROCO:6879) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$49.25, compared to a current price of NT$37.00 — trading 24.9% below its estimated fair value. The current FCF Margin % is 66.64%, which is 201% above median its 10-year median of 22.16. Tci Gene's overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Tci Gene (ROCO:6879), the current FCF Margin % is 66.64% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tci Gene (ROCO:6879) Overvalued in 2026?
Based on GuruFocus' analysis, Tci Gene stock appears to be undervalued.
The current stock price of NT$37.00 is trading 24.9% below its estimated GF Value™ of NT$49.25.
GuruFocus considers Tci Gene to be Modestly Undervalued.
Key valuation signals for ROCO:6879:
FCF Margin %: 66.64% (201% above median its 10-year median of 22.16)
GF Value™: NT$49.25 vs. price of NT$37.00 (24.9% below fair value)
No single metric tells the full story. See the ROCO:6879 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tci Gene Inc provides precision preventive medicines in Taiwan. It is the first to introduce the concept of precision preventive medicine with Predict prediction, Prevent prevention, and Personal Treatment personalized health management measures.
65GF Score
Get the complete analysis for ROCO:6879
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6879 has been successfully added to your 
